Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1036595 | 1.00 | DPP4 (0.50) | DPP4F2HTR2ATAAR1ADRA2A | |
| Hydrochloric Acid SCHEMBL4797236 | 0.97 | DPP4 (0.48) | DPP4F2HTR2ATAAR1ADRA2A | |
| SCHEMBL21263995 | 0.75 | CHRNA7 (0.39) | LMNAALDH1A1 | |
| SCHEMBL26033140 | 0.75 | HTT (0.40) | LMNAHIF1AKDM4EALDH1A1 | |
| SCHEMBL28185990 | 0.75 | ADRB2 (0.50) | ADRA2ALMNAHIF1AKDM4E | |
| SCHEMBL23244675 | 0.75 | PYCR1 (0.40) | DPP4HTR2AALDH1A1 | |
| SCHEMBL28185987 | 0.75 | IDO1 (0.43) | LMNAALDH1A1 | |
| SCHEMBL1036920 | 0.74 | DPP4 (0.50) | DPP4F2HTR2ATAAR1ADRA2A | |
| SCHEMBL1036918 | 0.74 | DPP4 (0.50) | DPP4F2HTR2ATAAR1ADRA2A | |
| SCHEMBL10404165 | 0.74 | DPP4 (0.50) | DPP4F2HTR2ATAAR1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202902-B2 | Bivalent SMAC mimetics and the uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202902-B2 | Bivalent SMAC mimetics and the uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-06-19 | — | — | US | disclosed |
| US-7960372-B2 | Inhibitors of apoptosis proteins; antiproliferative agents; kits | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960372-B2 | Inhibitors of apoptosis proteins; antiproliferative agents; kits | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090123480-A1 | BIVALENT SMAC MIMETICS AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090123480-A1 | BIVALENT SMAC MIMETICS AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-05-14 | — | — | US | disclosed |
| US-20080089896-A1 | Bivalent SMAC mimetics and the uses thereof | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080089896-A1 | Bivalent SMAC mimetics and the uses thereof | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080089896-A1 | Bivalent SMAC mimetics and the uses thereof | BID, BAD, BIRC2 | DPP4 4162/4885F2 3744/4885HTR2A 4344/4885 |
| US-20090123480-A1 | BIVALENT SMAC MIMETICS AND THE USES THEREOF | BID, BAD, BIRC2 | DPP4 4162/4885F2 3744/4885HTR2A 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.